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Abstract 
A simple, selective and rapid LC-ESI-MS/MS method has been developed and validated for the 
quantification of ivosidenib in mice plasma using warfarin as an internal standard (I.S.) as per 
regulatory guideline. Sample preparation was accomplished through a simple protein precipitation 
process. Chromatography of ivosidenib and the I.S. was achieved on an Atlantis dC18 column using an 
isocratic mobile phase comprising 0.2 % formic acid in water and acetonitrile (25:75, v/v) delivered at 
a flow rate of 1.0 mL/min. LC-MS/MS was operated under the multiple reaction-monitoring mode 
(MRM) using the electrospray ionization technique in positive ion mode and the transitions of m/z 
583.1→186.1 and m/z 309.2→251.3 were used to quantitate ivosidenib and the I.S, respectively. The 
total chromatographic run time was 2.0 min. Linearity was established in the concentration range of 
1.10-3293 ng/mL (r
2
>0.99). The intra- and inter-day accuracy and precision for ivosidenib in mice 
plasma were in the range of 5.72-9.91 and 5.90-10.7 %, respectively. Ivosidenib was found to be 
stable on bench-top for 6 h, up to three freeze-thaw cycles, in in-injector for 24 h and for one month 
at -80 °C. The applicability of the validated method has been demonstrated in a mice pharmacokinetic 
study. Following intravenous (2 mg/kg) and oral (5 mg/kg) administration of ivosidenib to mice, 
concentrations were quantifiable up to 24 and 48 h, respectively. The bioavailability was 61 %. 
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Introduction 
Isocitrate dehydrogenase isoforms (IDH1 and IDH2/3 located in cytoplasm and mitochondria, 
respectively) play a key role in normal cell growth and regulation. All three isoforms are responsible 
for the production of nicotinamide adenine dinucleotide phosphate (NADPH) from NADP+ by 
catalyzing the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) [1]. Recent 
investigations discovered that IDH1/2 mutations in 20 % of acute myeloid leukemia (AML) population 
and rarely in breast, lung and prostate cancers [2]. Targeting mutant IDH1/2 proved to be an option 
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for the treatment of AML as a targeted therapy alone or in combination with other antileukemic 
agents [3]. Ivosidenib (AG-120, Tibsovo®; Fig. 1), is a novel, first-in-class, oral small molecule, which 
selectively and reversibly inhibits mIDH1 (IC50: 12 nM) without any IDH2 inhibition (at micromolar 
concentration) along with good cellular potency. It showed tumor regression in mice xenograft model 
of IDH-mutated AML at 50 and 150 mg/kg doses [4]. Recently, FDA approved ivosidenib as an orphan 
drug for relapsed or refractory IDH1 mutant AML patients as detected by an FDA-approved test [5]. In 
humans as a monotherapy it is administered at a daily dose of 500 mg. Following oral administration 
Cmax (maximum concentration in plasma) attained at ~3 h (Tmax). It has shown less than dose 
proportional increase in AUC (area under concentration time curve) and Cmax from 200-1200 mg. 
Unchanged ivosidenib is majorly (92 %) seen in plasma. Ivosidenib is 92-96 % bound to plasma 
proteins. CYP3A4 mainly involved in its metabolism (N-dealkylation and hydrolysis). It is eliminated as 
parent up to 67 and 10 % in the feces and urine, respectively. The oral bioavailability was found to be 
57 % [5].  
 LC-MS/MS is a powerful tool for rapid quantitation of drugs in various biological matrices with 
great accuracy and sensitivity with a shorter run time. Preclinical pharmacokinetics has a great 
influence on the development and investigation of potential preclinical candidates with better advice 
for the further drug design. Pharmacokinetic studies in preclinical species can both provide 
toxicological and clinical information and direct optimization of drug candidates; as a result, they play 
necessary parts in drug discovery and development. To date there is no LC-MS/MS method reported 
for quantification of ivosidenib in any biological matrix. In this paper, we are reporting the 
development and validation of a sensitive, selective and rapid LC-ESI-MS/MS method for quantitation 
of ivosidenib in mice plasma. The validated method was successfully used in a mice pharmacokinetic 
study following intravenous and oral administration of ivosidenib at 2.0 and 5.0 mg/kg dose, 
respectively. 
Materials and methods  
Materials 
Ivosidenib (purity: 98 %) was purchased from Angene International Limited, England, UK. Warfarin 
(I.S; purity: 98.7 %) was purchased from Sigma-Aldrich, St. Louis, USA. LC-MS-grade acetonitrile and 
methanol were purchased from JT Baker, Avantor Performance Materials, PA, USA. Formic acid was 
purchased from Avra Synthesis Pvt. Ltd, Hyderabad, India. The control Balb/C mice K2.EDTA plasma 
sample was procured from Animal House, Jubilant Biosys. 
Instrumentation and chromatographic conditions  
A Shimadzu HPLC Prominence (Shimadzu, Japan) coupled with Sciex 6500 triple quadrupole (Sciex, 
Redwood City, CA, USA) mass spectrometer was used for all analyses. The instrument was controlled 
using Analyst software (version 1.6.2). Ivosidenib and the I.S. were eluted using an isocratic mobile 
phase, which is a mixture of 0.2 % formic acid in water and acetonitrile (25:75, v/v) and 
chromatographed on an Atlantis dC18 column (50  4.6 mm, 3 m) maintained at 40 ± 1 °C. The flow-
rate was 1.0 mL/min. The mass spectrometer was operated in the multiple reaction mode (MRM) 
with positive electrospray ionization for the quantitation of ivosidenib and the I.S. Ionization was 
conducted by applying a voltage of 5500 V and source temperature was set at 500 °C. For analyte and 
the IS the optimized source parameters viz., curtain gas, GS1, GS2 and CAD were set at 55, 55, 65 and 
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10 psi. The compound parameters viz., declustering potential (DP), entrance potential (EP), collision 
energy (CE) and collision cell exit potential (CXP) 78, 10, 36, and 5 V for ivosidenib and 61, 10, 20, and 
18 V for the IS. The mass transition m/z (precursor ion  product ion) 583.1186.1 and 
309.2251.3 were monitored for ivosidenib and the I.S, respectively. Quadrupole Q1 and Q3 were 
set on unit resolution. The dwell time was 100 msec.  
Preparation of stock and standard solutions  
Primary stock solutions of ivosidenib for preparation of calibration curve (CC) and quality control 
(QC) samples were prepared from separate weighing. The primary stock solution of ivosidenib (1144 
µg/mL) and the I.S. (1000 µg/mL) were made in methanol:water (80:20, v/v) and DMSO, respectively. 
The primary stock solution of ivosidenib and the I.S. were stored at -20°C, which were found to be 
stable for 45 days. Ivosidenib primary stock solution was successively diluted in methanol:water 
(80:20, v/v) to prepare secondary stock and working stock solutions, which were used to prepare CCs 
and QCs. Working stock solutions were stored approximately at 4 °C for ten days. A working stock of 
the I.S. solution (100 ng/mL) was prepared in methanol. Samples for the determination of precision 
and accuracy were prepared by spiking control mice plasma in bulk with ivosidenib at appropriate 
concentrations: 1.10 ng/mL (lower limit of quantitation quality control, LLOQ QC), 3.29 ng/mL (low 
quality control, LQC), 1715 ng/mL (medium quality control, MQC) and 2607 ng/mL (high quality 
control, HQC) and were stored at -80 ± 10 °C until analysis. 
Sample preparation 
To an aliquot of 10 µL plasma, 500 µL of methanol containing 100 ng/mL I.S. was added and vortex 
mixed for 2 min. Thereafter the contents were centrifuged for 5 min at 14,000 rpm in a refrigerated 
centrifuge (Eppendorf 5424R) maintained at 5 °C. Clear supernatant (200 µL) was transferred into vials 
and 2.0 µL was injected onto LC-MS/MS system for analysis. 
Validation procedures 
The validation experiments were performed in accordance with the US Food and Drug 
Administration guideline [6].  
The selectivity of the method was determined by the presence of interfering peaks from six 
individual drug-free mice plasma samples at the retention times of ivosidenib and the I.S. The auto-
injector carryover was determined by injecting the highest calibration standard, followed by injection 
of blank plasma samples.  
The LLOQ was determined as the concentration that has a precision of <20 % of the relative 
standard deviation and accuracy between 80-120 % of the theoretical value. The response of the 
blanks was then compared to that of the LLOQ.  
Recovery was determined at LQC and HQC. Recovery for ivosidenib was calculated by comparing 
the mean peak response of pre-extraction spiked samples (spiked before extraction; n=6) to that of 
neat samples (n=6) at each QC level. Matrix effect was assessed by comparing the analyte mean peak 
areas at LQC and HQC concentration after extraction with the mean peak areas for post extracted 
blank plasma samples spiked with analyte at equivalent concentrations. Recovery and matrix effect 
for the I.S. was assessed at single concentration (100 ng/mL).  
The precision and accuracy of the method were evaluated by measuring the four QC samples 
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(LLOQ QC, LQC, MQC and HQC), which were prepared on each validation day (n=6 each). Inter-day 
precision was assessed on four separate days. Inter- and intra-day precisions were determined by 
calculating percent relative standard deviation (%RSD) that should be 15 % for all QCs except for 
LLOQ QC where it should be 20 %. The inter- and intra-day accuracy expressed as percent relative 
error (%RE) was calculated by comparing the measured concentration with the nominal value and 
deviation was limited within ±15 % except for LLOQ QC where it should be 20 %.  
Freeze-thaw stability following three freeze-thaw cycles was evaluated (one day duration between 
each freeze-thaw cycle and ivosidenib spiked plasma samples were stored in -80 ± 10 °C between 
freeze/thaw cycles). The plasma samples were thawed at room temperature for 1 h and returned to 
the freezer. Bench-top stability was assessed by analyzing samples that had been kept at ambient 
temperature (25 ± 1 °C) for 6 h. Long-term stability was performed by analyzing samples that had 
been stored at -80 ± 10 °C for 30 days. The stability of ivosidenib and the I.S. in the injection solvent 
was determined periodically by injecting replicate preparations of processed plasma samples for up to 
24 h (in the auto-sampler at 5 °C) after the initial injection. The peak-areas of the analyte and the I.S. 
obtained at initial cycle were used as the reference to determine the stability at subsequent points. 
These stability samples were processed and quantified against freshly spiked calibration curve 
standards along with freshly spiked QC samples. Samples were considered to be stable if assay values 
were within the acceptable limits of accuracy (±15 % RE) and precision (20 % RSD).  
To evaluate the effect of dilution over the calibration range, the accuracy and precision of dilution 
control samples at 9881 ng/mL (n=6; 3 times of the ULOQ) were assessed by performing a 5- and 10-
fold dilution. 
Pharmacokinetic study in mice  
All the animal experiments were approved by Institutional Animal Ethical Committee 
(IAEC/JDC/2017/133). Male Balb/C mice (n=24) were procured from Vivo Biotech, Hyderabad, India. 
The animals were housed in Jubilant Biosys animal house facility in a temperature (22 ± 2 °C) and 
humidity (30-70 %) controlled room (15 air changes/hour) with a 12:12 h light:dark cycles, had free 
access to rodent feed (Altromin Spezialfutter GmbH & Co. KG., Im Seelenkamp 20, D-32791, Lage, 
Germany) and water for one week before using for experimental purpose. Following 4 h fast (during 
the fasting period animals had free access to water) animals were divided into two groups 
(n=12/group). Group I animals (26-30 g) received ivosidenib orally at 5.0 mg/kg (suspension 
formulation comprising 0.5 % Tween-80 and methyl cellulose (0.5 % in water); strength: 0.5 mg/mL; 
dose volume: 10 mL/kg), whereas Group II animals (27-31 g) received ivosidenib intravenously [5 % 
DMSO, 5 % Solutol:absolute alcohol (1:1, v/v) and 90 % of normal saline; strength: 0.2 mg/mL; dose 
volume: 10 mL/kg] at 2.0 mg/kg dose. Post-dosing serial blood samples (40 µL, sparse sampling was 
done and at each time point three mice were used for blood sampling) were collected using 
Micropipettes (Microcaps®; catalogue number: 1-000-0500) through tail vein into polypropylene 
tubes containing K2EDTA solution as an anti-coagulant at 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24, 30, 36 and 48 
h (for oral study) and 0.12, 0.25, 0.5, 1, 2, 4, 8, 10, 12, 24 and 36 h (for intravenous study). Plasma was 
harvested by centrifuging the blood using Biofuge (Hereaus, Germany) at 1760 g for 5 min and stored 
frozen at -80 ± 10 °C until analysis. Animals were allowed to access feed 2 h post-dosing. 
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Results and discussion 
Liquid chromatography and MS/MS conditions  
To avoid the potentially co-eluting peaks from blank plasma, which will influence the ionization 
efficiency of ivosidenib and the I.S, the mobile phase was optimized along with chromatographic 
conditions. In order to get chromatograms with good separation, peak shape and resolution for 
ivosidenib and the I.S, feasibility of various mixture(s) of solvents such as acetonitrile and methanol 
using different buffers such as ammonium acetate, ammonium formate and formic acid along with 
altered flow-rates (in the range of 0.8-1.2 mL/min) were tested. The resolution of ivosidenib and the 
I.S. was achieved with 0.2 % formic acid:acetonitrile (25:75, v/v) at a flow rate of 1.0 mL/min. Atlantis 
dC18 column (100  4.6 mm, 3 µm) was best suited to provide the symmetric peaks and baseline 
separation of ivosidenib and the I.S. with the retention time of 0.96 and 1.02 min, respectively. The 
total chromatographic run time was 2.0 min.  
To obtain optimum ionization and sensitivity 100 ng/mL ivosidenib solution was directly injected 
into mass spectrometer and electrospray ionization (ESI) full scans were carried out both in positive 
and negative ion detection modes. Positive ESI mode was chosen as it provided good intensity signals 
and formed protonated [M+H]
+
 at m/z 583.1. This precursor ion (Q1) was selected for fragmentation 
in MS/MS mode to obtain most intense and consistent product ion (Q3: m/z 186.1) by optimizing the 
declustering potential, collision energy and collision cell exit potential. Subsequently, various gases 
like nebulizer gas (GS1), auxiliary gas (GS2), collision gas and source temperature were optimized to 
obtain adequate and reproducible response. MRM mode was used to obtain better selectivity, with 
dwell time of 100 ms for each transition. Fragment ions at m/z 476, 214, 186 and 158 were produced 
as prominent product ions for ivosidenib due to sequential loss of m/z 107, 262, 28 and 28 from 
ivosidenib. The postulated fragmentation pattern of ivosidenib is shown in Figure 1. Due to non-
availability of deuterated ivosidenib to use it as an I.S, we have used warfarin as an I.S. and found to 
be the best for present purpose based on the chromatographic elution, ionization and reproducible 
and good extraction efficiency. For quantitation purpose m/z 583.1 precursor ion to the m/z 186.1 and 
m/z 309.2 precursor ion to the m/z 251.3 was used for ivosidenib and the I.S, respectively.  
 
Figure 1. Fragmentation pattern of ivosidenib 




Among the tested drug-free mice blank plasma samples no sample shown any interference at the 
retention times of the ivosidenib and the I.S. indicating that the method is selective (Figure 2).  
 
 
(a) mice blank plasma (b) I.S. (c) ivosidenib LLOQ (d) 0.25 h plasma sample 
Figure 2. Typical MRM chromatograms of (a) mice blank sample (b) mice blank plasma spiked with I.S. (c) 
mice blank plasma spiked with ivosidenib at LLOQ (1.10 ng/mL) and (d) 0.25 h plasma sample showing 
ivosidenib (1953 ng/mL) peak obtained following 5.0 mg/kg oral dose of ivosidenib to mice. 
Sensitivity and carry over 
The lowest limit of reliable quantification for the analyte was set at the concentration of the LLOQ. 
The precision and accuracy at LLOQ concentration were found to be 6.12 and 91.0 % for ivosidenib. 
There was no carry-over produced by the highest calibration sample on the following injected blank 
plasma extract sample.  
Recovery 
The mean ± S.D recovery at LQC and HQC was found to be 66.5 ± 8.97 and 76.1 ± 1.43 %, 
respectively. The recovery of the I.S. was 100 ± 8.99 %.  
Matrix effect 
Six different lots of plasma samples, spiked with analyte concentration levels at LQC and HQC levels 
were analyzed. Matrix effect for ivosidenib at LQC and HQC was 0.99 ± 6.82 and 1.04 ± 1.70 %, 
respectively. The matrix effect for the I.S. was 1.09 ± 4.13%. The results have shown that the precision 
and accuracy for analyzed samples were within acceptance range. Overall it was found that there is no 
impact on the ionization of analyte and the I.S. 
Calibration curve 
The plasma calibration curve was constructed using eight calibration standards (viz., 1.10, 2.20, 
21.9, 109, 548, 1097, 2264 and 3293 ng/mL). Under the analytical conditions used in the present 
study, the calibration curves of ivosidenib were found to be linear. Calibration curve was prepared by 
determining the best fit of peak-area ratios (peak area analyte/peak area IS) versus concentration, and 
fitted to the y = mx + c using weighing factor (1/X2). The average slope and intercept values were 
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found to be 0.001173 and 0.00014, respectively. The average regression (n=4) was found to be 
0.995. The lowest concentration with the RSD < 20 % was taken as LLOQ
 
and was found to be 1.10 
ng/mL. The % accuracy observed for the mean of back-calculated concentrations for four calibration 
curves for ivosidenib was within 90.8-110; while the precision (%RSD) values ranged from 2.08-9.42. 
Accuracy and precision 
A summary of the accuracy and precision data for intra- and inter-day is listed in Table 1. The assay 
values on both the occasions (intra- and inter-day) were found to be within the accepted variable 
limits.  












Mean ± S.D 1.09 ± 0.11 3.20 ± 0.28  1631 ± 96.2 2582 ± 188 
Precision (%RSD) 9.91 8.86 5.72 7.31 
Accuracy (%RE) 0.99 0.97 0.98 0.99 
Inter-day (n=24) 
Mean ± S.D 1.10 ± 0.12 3.19 ± 0.27  1634 ± 96.4 2588 ± 188 
Precision (%RSD) 10.7 8.48 5.90 7.25 
Accuracy (%RE) 1.00 0.97 0.95 0.99 
%RE: relative error (measured value/actual value ×100) 
RSD: relative standard deviation (SD × 100/Mean) 
SD: standard deviation 
Stability 
The predicted concentrations for ivosidenib at 3.29 ng/mL
 





a battery of stability tests namely in-injector (24 h), bench-top (6 h), repeated three freeze/thaw 
cycles and freezer stability at -80  10 °C for 30 days are shown in Table 2. The results were found to 
be within the assay variability limits during the entire process.  
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2.98 ± 0.20 
3.39 ± 0.50 
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2632 ± 110 












 Back-calculated plasma concentrations 
b
 (Mean assayed concentration / mean assayed concentration at 0 h) × 100 
 %RE: relative error (measured value/actual value × 100) 
 RSD: relative standard deviation (SD × 100/Mean) 
Dilution effect  
The accuracy and precision of the nominal concentration of the diluted plasma samples were 
within 0.79 % and 3.34 %, which show the ability to dilute samples up to a dilution factor of 10-fold in 
a linear fashion. 
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Pharmacokinetic study 
The sensitivity and specificity of the validated assay was found to be sufficient for accurately 
characterizing the pharmacokinetics of ivosidenib in mice plasma following intravenous and oral 
administration. The estimates of the pharmacokinetic parameters are summarized in Table 3. The 
mean plasma concentration versus time profiles for ivosidenib following single oral and intravenous 
route is depicted in Figures 3A and 3B, respectively. Following intravenous administration, the plasma 
concentrations decreased in a mono-exponential manner. Ivosidenib was quantifiable up to 24 h post-
dosing by intravenous route. The AUC0- (area under curve from time zero to infinity) was found to be 
4967 ng  h/mL. The in vivo clearance (CL) and volume of distribution (Vd) was found to be 6.85 
mL/min/kg and 1.70 L/kg, indicating that ivosidenib has low clearance and moderate volume of 
distribution. After oral administration of ivosidenib to mice, maximum concentration in plasma (Cmax: 
1668 ng/mL) attained at 0.50 h (Tmax) indicating rapid absorption from gastrointestinal tract. Ivosidenib 
was quantifiable up to 36 h post oral dosing. The AUC(0-) was found to be 7462 ng  h/mL. The 
terminal half-life was 2.87 and 4.06 h, by intravenous and oral routes, respectively. The absolute oral 
bioavailability was 61 %. 
Table 3. Pharmacokinetic parameters of ivosidenib in mice 
Parameter Intravenous Oral 
Dose      (mg/kg) 2.0 5.0 
AUC0-∞  (ng × h/mL) 4967 7462 
C0/Cmax  (ng/mL) 6085 1668 
Tmax         (h) --- 0.50 
t1/2         (h) 2.87 4.06 
CL        (mL/min/kg) 6.85 --- 





































































































Figure 3. Mean plasma concentration-time profile of ivosidenib following (A) intravenous and (B) oral 
dosing to mice 
Conclusions 
A rapid, simple, sensitive and selective LC-ESI-MS/MS method was developed and validated for the 
determination of ivosidenib using 10 µL mice plasma. This method demonstrates good accuracy and 
precision and meets US FDA validation criteria. To our knowledge, this is the first report of an LC-
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MS/MS method for quantification of ivosidenib in plasma and successfully applied for a 
pharmacokinetic study in mice. 
 
Conflict of interest: The authors wish to declare that there are no conflicts of interests in the contents 
of the manuscript. 
References  
[1] Z.J. Reitman, H. Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a 
crossroads of cellular metabolism. Journal of National Cancer Institute 102 (2010) 932-941.  
[2] E. Stein, K. Yen. Targeted differentiation therapy with mutant IDH inhibitors: Early experiences 
and parallels with other differentiation agents. Annual Reviews in Cancer Biology 1 (2017) 379-
401. 
[3] M.J. Buege, A.J. DiPippo, C.D. DiNardo. Evolving treatment strategies for elder leukemia 
patients with IDH mutations. Cancers 10 (2018) E187. 
[4] J. Popovici-Muller, R.M. Lemieux, E. Artin, J.O. Saunders, F.G. Salituro, J. Travins et al. 
Discovery of AG-120 (Ivosidenib): A first-in-class mutant IDH1 inhibitor for the treatment of 
IDH1 mutant cancers. ACS Medicinal Chemistry Letters 9 (2018) 300-305. 
[5] Tibsovo (ivosidenib) prescribing information, Agios Pharmaceuticals, Inc, July 2018. Available 
at www.accessdata.fda.gov. Accessed November 9, 2018.  
[6] US DHHS, FDA, CDER, CVM. Guidance for Industry: Bioanalytical Method Validation. U.S. 
Department of Health and Human Services, Food and Drug Administration, Center for Drug 














©2019 by the authors; licensee IAPC, Zagreb, Croatia. This article is an open-access article distributed under the terms and 
conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/)  
 
